-DOCSTART- -X- O
The -X- _ O
development -X- _ O
and -X- _ O
implementation -X- _ O
of -X- _ O
highly -X- _ B-Intervention
multiplexed -X- _ I-Intervention
molecular -X- _ I-Intervention
diagnostic -X- _ I-Intervention
tests -X- _ I-Intervention
have -X- _ O
allowed -X- _ O
clinical -X- _ O
microbiology -X- _ O
laboratories -X- _ O
to -X- _ O
more -X- _ O
rapidly -X- _ O
and -X- _ O
sensitively -X- _ O
detect -X- _ O
a -X- _ O
variety -X- _ O
of -X- _ O
pathogens -X- _ O
directly -X- _ O
in -X- _ O
clinical -X- _ O
specimens. -X- _ O
Current -X- _ O
US -X- _ B-Intervention
Food -X- _ I-Intervention
and -X- _ I-Intervention
Drug -X- _ I-Intervention
Administrationâ€“approved -X- _ I-Intervention
multiplex -X- _ I-Intervention
panels -X- _ I-Intervention
target -X- _ O
multiple -X- _ O
different -X- _ O
organisms -X- _ O
simultaneously -X- _ O
and -X- _ O
can -X- _ O
identify -X- _ O
the -X- _ O
most -X- _ O
common -X- _ O
pathogens -X- _ O
implicated -X- _ O
in -X- _ O
respiratory -X- _ O
viral -X- _ O
, -X- _ O
gastrointestinal -X- _ O
, -X- _ O
or -X- _ O
central -X- _ O
nervous -X- _ O
system -X- _ O
infections. -X- _ O
This -X- _ O
review -X- _ O
summarizes -X- _ O
the -X- _ O
test -X- _ O
characteristics -X- _ O
of -X- _ O
available -X- _ O
assays -X- _ O
, -X- _ O
highlights -X- _ O
the -X- _ O
advantages -X- _ O
and -X- _ O
limitations -X- _ O
of -X- _ O
multiplex -X- _ O
technology -X- _ O
for -X- _ O
infectious -X- _ B-Patient
diseases -X- _ I-Patient
, -X- _ O
and -X- _ O
discusses -X- _ O
potential -X- _ O
utilization -X- _ O
of -X- _ O
these -X- _ O
new -X- _ O
tests -X- _ O
in -X- _ O
clinical -X- _ B-Outcome
practice -X- _ I-Outcome
. -X- _ O

